The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

被引:7
|
作者
Jamous, Yahya F. [1 ]
Alhomoud, Dalal A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol, Natl Ctr Vaccine & Bioproc, Riyadh, Saudi Arabia
关键词
safety; efficacy; vaccines; mrna; sars-cov-2; COVID-19; VACCINE; HYPERSENSITIVITY; OUTCOMES; SEX;
D O I
10.7759/cureus.45602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and PfizerBioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Maintaining Safety with SARS-CoV-2 Vaccines Reply
    Castells, Mariana C.
    Phillips, Elizabeth J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10): : e37 - e37
  • [22] Timely development of vaccines against SARS-CoV-2
    Lu, Shan
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 542 - 544
  • [23] Ensuring Uptake of Vaccines against SARS-CoV-2
    Mello, Michelle M.
    Silverman, Ross D.
    Omer, Saad B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14): : 1296 - 1299
  • [24] Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis
    Ling, Yunzhi
    Zhong, Jiaying
    Luo, Jiaru
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6486 - 6495
  • [25] Messenger RNA vaccines against SARS-CoV-2
    Topol, Eric J.
    CELL, 2021, 184 (06) : 1401 - 1401
  • [26] The development of DNA vaccines against SARS-CoV-2
    Khalid, Kanwal
    Poh, Chit Laa
    ADVANCES IN MEDICAL SCIENCES, 2023, 68 (02): : 213 - 226
  • [27] mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
    Yi, Changhua
    Yi, Yongxiang
    Li, Junwei
    VIROLOGICA SINICA, 2020, 35 (03) : 259 - 262
  • [28] Nucleic Acid Vaccines against SARS-CoV-2
    Liu, Ying
    Ye, Qing
    VACCINES, 2022, 10 (11)
  • [29] Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
    Hajissa, Khalid
    Mussa, Ali
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (08) : 2445 - 2447
  • [30] Hypereosinophilia after vaccination with the SARS-CoV-2 mRNA vaccines
    Westreich, Aaron
    Zelarney, Pearlanne
    Wechsler, Michael E.
    PROGRESS IN NATURAL SCIENCE-MATERIALS INTERNATIONAL, 2023, 11 (05) : 1564 - 1566